Generics in France

Introduction

Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the France generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices. Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume. All currency conversions were calculated at constant average annual 2011 exchange rates.

*The French generics market had total revenues of $4,268.3 million in 2011, representing a compound annual growth rate (CAGR) of 7.6% between 2007 and 2011.

*Market consumption volumes increased with a CAGR of 15.7% between 2007 and 2011, to reach 44.8% of total pharma market volume in 2011.

*The performance of the market is forecast to decelerate, with an anticipated CAGR of 3% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $4,949.6 million by the end of 2016.

Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in France

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts

Macroeconomic indicators provide insight into general trends within the France economy

Key Questions Answered

What was the size of the France generics market by value in 2011?

What will be the size of the France generics market in 2016?

What factors are affecting the strength of competition in the France generics market?

How has the market performed over the last five years?

Generic Drug Industry in France

TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Les Laboratories Servier 19
Mylan Inc 20
Novartis AG 23
Sanofi 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related MarketLine research 32

LIST OF TABLES
Table 1: France generics market value: $ billion, 2007–11 8
Table 2: France generics market volume: % of total Pharma volume, 2007–11 9
Table 3: France generics market geography segmentation: $ billion, 2011 10
Table 4: France generics market value forecast: $ billion, 2011–16 11
Table 5: France generics market volume forecast: % of total Pharma volume, 2011–16 12
Table 6: Les Laboratories Servier: key facts 19
Table 7: Mylan Inc: key facts 20
Table 8: Mylan Inc: key financials ($) 20
Table 9: Mylan Inc: key financial ratios 21
Table 10: Novartis AG: key facts 23
Table 11: Novartis AG: key financials ($) 24
Table 12: Novartis AG: key financial ratios 24
Table 13: Sanofi: key facts 26
Table 14: Sanofi: key financials ($) 27
Table 15: Sanofi: key financials (€) 27
Table 16: Sanofi: key financial ratios 27
Table 17: France size of population (million), 2007–11 29
Table 18: France gdp (constant 2000 prices, $ billion), 2007–11 29
Table 19: France gdp (current prices, $ billion), 2007–11 29
Table 20: France inflation, 2007–11 30
Table 21: France consumer price index (absolute), 2007–11 30
Table 22: France exchange rate, 2007–11 30

LIST OF FIGURES
Figure 1: France generics market value: $ billion, 2007–11 8
Figure 2: France generics market volume: % of total Pharma volume, 2007–11 9
Figure 3: France generics market geography segmentation: % share, by value, 2011 10
Figure 4: France generics market value forecast: $ billion, 2011–16 11
Figure 5: France generics market volume forecast: % of total Pharma volume, 2011–16 12
Figure 6: Forces driving competition in the generics market in France, 2011 13
Figure 7: Drivers of buyer power in the generics market in France, 2011 14
Figure 8: Drivers of supplier power in the generics market in France, 2011 15
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2011 16
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2011 17
Figure 11: Drivers of degree of rivalry in the generics market in France, 2011 18
Figure 12: Mylan Inc: revenues & profitability 21
Figure 13: Mylan Inc: assets & liabilities 22
Figure 14: Novartis AG: revenues & profitability 24
Figure 15: Novartis AG: assets & liabilities 25
Figure 16: Sanofi: revenues & profitability 28
Figure 17: Sanofi: assets & liabilities 28

Generic Drug in France

France Generic Drug Sales, Us$bn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2007 To 2021
By Business Monitor International
Source: European Generics Association (EGA), European Federation of Pharmaceutical Industries and Associatio

• Industries : Generic Drug
• Countries : France, Europe

France Generic Drug Sales, Us$bn

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2021
By Business Monitor International
Source: European Generics Association (EGA), European Federation of Pharmaceutical Industries and Associatio

• Industries : Generic Drug
• Countries : France, Europe

France Generic Drug Sales, Eurbn

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2021
By Business Monitor International
Source: European Generics Association (EGA), European Federation of Pharmaceutical Industries and Associatio

• Industries : Generic Drug
• Countries : France, Europe

France Generic Drug Sales, Eurbn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2007 To 2021
By Business Monitor International
Source: European Generics Association (EGA), European Federation of Pharmaceutical Industries and Associatio

• Industries : Generic Drug
• Countries : France, Europe

France Generic Drug Sales, % Of Total Sales

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2021
By Business Monitor International
Source: European Generics Association (EGA), European Federation of Pharmaceutical Industries and Associatio

• Industries : Generic Drug
• Countries : France, Europe